Search Within

Carol A Aghajanian

Formats
  1. Journal Article (325)
  2. Meeting Abstract (284)
  3. Review (3)
  4. Book Section (1)
  5. Correspondence (1)
  6. Editorial (1)
Groups
  1. Department of Medicine (615)
  2. GDMT, Medicine (615)
  3. Gynecologic Medicine Service (615)
  4. Gynecology Disease Management Team (615)
  5. Solid Tumor Oncology Division (615)
  6. Surgery (229)

More Groups

People
  1. Nadeem Abu-Rustum (126)
  2. Paul Sabbatini (125)
  3. Alexia Iasonos (116)
  4. David Spriggs (105)
  5. Roisin O'Cearbhaill (99)
  6. Martee Hensley (94)

More People

Years
  1. 2025 (24)
  2. 2024 (38)
  3. 2023 (42)
  4. 2022 (45)
  5. 2021 (35)
  6. 2020 (61)

More Years

Publications
  1. Gynecologic Oncology (200)
  2. Journal of Clinical Oncology (150)
  3. International Journal of Gynecological Cancer (57)
  4. Clinical Cancer Research (30)
  5. Annals of Oncology (28)
  6. Cancer (15)

More Publications

Publishers
  1. Elsevier B.V. (204)
  2. American Society of Clinical Oncology (156)
  3. Lippincott Williams & Wilkins (59)
  4. American Association for Cancer Research (54)
  5. Oxford University Press (30)
  6. Elsevier Inc. (21)

More Publishers

Results (615)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: An MSK Team Ovary phase II study
    Journal Article

    Zivanovic, O.; Chi, D. S.; Zhou, Q.; Iasonos, A.; Konner, J. A.; Makker, V.; Grisham, R. N.; Brown, A. K.; Nerenstone, S.; Diaz, J. P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Diagnosis and management of an endometrial cancer patient with Cowden syndrome
    Journal Article

    Manning-Geist, B. L.; Gatius, S.; Liu, Y.; Gil, M.; Da Cruz Paula, A.; Tuset, N.; Abu-Rustum, N. R.; Aghajanian, C.; Weigelt, B.; Matias-Guiu, X.
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save
  • Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
    Journal Article

    Colombo, N.; Moore, K.; Scambia, G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; Gourley, C.; more...
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save
  • Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety
    Journal Article

    Oaknin, A.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; Leary, A.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer
    Journal Article

    Kyi, C.; Doubrovina, E.; Zhou, Q.; Kravetz, S.; Iasonos, A.; Aghajanian, C.; Sabbatini, P.; Spriggs, D.; O'Reilly, R. J.; O'Cearbhaill, R. E.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Secondary efficacy results from the phase II LIGHT study
    Meeting Abstract

    Cadoo, K.; Simpkins, F.; Mathews, C.; Liu, Y.; Provencher, D.; McCormick, C.; ElNaggar, A.; Kabil, N.; Bennett, J.; Yu, H.; more...
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save
  • Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Secondary safety results from the phase II LIGHT study
    Meeting Abstract

    Cadoo, K.; Simpkins, F.; Mathews, C.; Altman, A.; Gilbert, L.; Liu, Y.; Black, D.; Munley, J.; Kabil, N.; Bennett, J.; more...
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save
  • Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: Exploratory analyses of IMagyn050/GOG3015/ENGOT-ov39
    Meeting Abstract

    Landen, C.; Molinero, L.; Sehouli, J.; Miller, A.; Moore, K.; Taskiran, C.; Bookman, M.; Lindemann, K.; Anderson, C.; Berger, R.; more...
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save
  • Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1
    Meeting Abstract

    Bradley, W.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; more...
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save
  • Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial
    Journal Article

    Aghajanian, C.; Bookman, M. A.; Fleming, G. F.; Swisher, E. M.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; Gunderson Jackson, C.; Sullivan, D.; Ratajczak, C. K.; more...
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save